FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315698723> ?p ?o ?g. }

• W4315698723 endingPage "611" @default.
• W4315698723 startingPage "601" @default.
• W4315698723 abstract "This multi-center, open-label, randomized, parallel-controlled phase II study aimed to compare the pharmacokinetics (PK), pharmacodynamics (PD) and safety profile of ripertamab (SCT400), a recombinant anti-CD20 monoclonal antibody, to rituximab (MabThera®) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL).Patients with CD20-positive B-cell NHL who achieved complete remission or unconfirmed complete remission after standard treatment were randomly assigned at a 1:1 ratio to receive a single dose of ripertamab (375 mg/m2) or rituximab (MabThera®, 375 mg/m2). PK was evaluated using area under the concentration-time curve (AUC) from time 0 to d 85 (AUC0-85 d), AUC from time 0 to week 1 (AUC0-1 w), AUC from time 0 to week 2 (AUC0-2 w), AUC from time 0 to week 3 (AUC0-3 w), AUC from time 0 to week 8 (AUC0-8 w), maximum serum concentration (Cmax), terminal half-life (T1/2), time to maximum serum concentration (Tmax) and clearance (CL). Bioequivalence was confirmed if the 90% confidence interval (90% CI) of the geometric mean ratio of ripertamab/rituximab was within the pre-defined bioequivalence range of 80.0%-125.0%. PD, immunogenicity, and safety were also evaluated.From December 30, 2014 to November 24, 2015, a total of 84 patients were randomized (ripertamab, n=42; rituximab, n=42) and the PK analysis was performed on 76 patients (ripertamab, n=38; rituximab, n=38). The geometric mean ratios of ripertamab/rituximab for AUC0-85 d, AUC0-inf, and Cmax were 96.1% (90% CI: 87.6%-105.5%), 95.9% (90% CI: 86.5%-106.4%) and 97.4% (90% CI: 91.6%-103.6%), respectively. All PK parameters met the pre-defined bioequivalence range of 80.0%-125.0%. For PD and safety evaluation, there was no statistical difference in peripheral CD19-positive B-cell counts and CD20-positive B-cell counts at each visit, and no difference in the incidence of anti-drug antibodies was observed between the two groups. The incidences of treatment-emergent adverse events and treatment-related adverse events were also comparable between the two groups.In this study, the PK, PD, immunogenicity, and safety profile of ripertamab (SCT400) were similar to rituximab (MabThera®) in Chinese patients with CD20-positive B-cell NHL." @default.
• W4315698723 created "2023-01-12" @default.
• W4315698723 creator A5000432967 @default.
• W4315698723 creator A5001104633 @default.
• W4315698723 creator A5008382997 @default.
• W4315698723 creator A5016769551 @default.
• W4315698723 creator A5018951895 @default.
• W4315698723 creator A5019544133 @default.
• W4315698723 creator A5025565506 @default.
• W4315698723 creator A5028634125 @default.
• W4315698723 creator A5030244343 @default.
• W4315698723 creator A5044808093 @default.
• W4315698723 creator A5049866755 @default.
• W4315698723 creator A5053708169 @default.
• W4315698723 creator A5062168574 @default.
• W4315698723 creator A5069456938 @default.
• W4315698723 creator A5076428327 @default.
• W4315698723 creator A5077970092 @default.
• W4315698723 creator A5082854379 @default.
• W4315698723 creator A5088363904 @default.
• W4315698723 date "2022-01-01" @default.
• W4315698723 modified "2023-10-16" @default.
• W4315698723 title "A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma" @default.
• W4315698723 cites W1793094955 @default.
• W4315698723 cites W1912693401 @default.
• W4315698723 cites W1915689252 @default.
• W4315698723 cites W1945251789 @default.
• W4315698723 cites W1978235999 @default.
• W4315698723 cites W2030437282 @default.
• W4315698723 cites W2058015212 @default.
• W4315698723 cites W206701898 @default.
• W4315698723 cites W2101648653 @default.
• W4315698723 cites W2104334201 @default.
• W4315698723 cites W2114676941 @default.
• W4315698723 cites W2160305510 @default.
• W4315698723 cites W2399930632 @default.
• W4315698723 cites W2790882914 @default.
• W4315698723 cites W2917304980 @default.
• W4315698723 cites W3042675424 @default.
• W4315698723 cites W3178726627 @default.
• W4315698723 doi "https://doi.org/10.21147/j.issn.1000-9604.2022.06.08" @default.
• W4315698723 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36714342" @default.
• W4315698723 hasPublicationYear "2022" @default.
• W4315698723 type Work @default.
• W4315698723 citedByCount "1" @default.
• W4315698723 countsByYear W43156987232023 @default.
• W4315698723 crossrefType "journal-article" @default.
• W4315698723 hasAuthorship W4315698723A5000432967 @default.
• W4315698723 hasAuthorship W4315698723A5001104633 @default.
• W4315698723 hasAuthorship W4315698723A5008382997 @default.
• W4315698723 hasAuthorship W4315698723A5016769551 @default.
• W4315698723 hasAuthorship W4315698723A5018951895 @default.
• W4315698723 hasAuthorship W4315698723A5019544133 @default.
• W4315698723 hasAuthorship W4315698723A5025565506 @default.
• W4315698723 hasAuthorship W4315698723A5028634125 @default.
• W4315698723 hasAuthorship W4315698723A5030244343 @default.
• W4315698723 hasAuthorship W4315698723A5044808093 @default.
• W4315698723 hasAuthorship W4315698723A5049866755 @default.
• W4315698723 hasAuthorship W4315698723A5053708169 @default.
• W4315698723 hasAuthorship W4315698723A5062168574 @default.
• W4315698723 hasAuthorship W4315698723A5069456938 @default.
• W4315698723 hasAuthorship W4315698723A5076428327 @default.
• W4315698723 hasAuthorship W4315698723A5077970092 @default.
• W4315698723 hasAuthorship W4315698723A5082854379 @default.
• W4315698723 hasAuthorship W4315698723A5088363904 @default.
• W4315698723 hasBestOaLocation W43156987231 @default.
• W4315698723 hasConcept C111113717 @default.
• W4315698723 hasConcept C112705442 @default.
• W4315698723 hasConcept C126322002 @default.
• W4315698723 hasConcept C22979827 @default.
• W4315698723 hasConcept C2779338263 @default.
• W4315698723 hasConcept C2780653079 @default.
• W4315698723 hasConcept C42404028 @default.
• W4315698723 hasConcept C44249647 @default.
• W4315698723 hasConcept C71924100 @default.
• W4315698723 hasConcept C76318530 @default.
• W4315698723 hasConcept C90924648 @default.
• W4315698723 hasConcept C98274493 @default.
• W4315698723 hasConceptScore W4315698723C111113717 @default.
• W4315698723 hasConceptScore W4315698723C112705442 @default.
• W4315698723 hasConceptScore W4315698723C126322002 @default.
• W4315698723 hasConceptScore W4315698723C22979827 @default.
• W4315698723 hasConceptScore W4315698723C2779338263 @default.
• W4315698723 hasConceptScore W4315698723C2780653079 @default.
• W4315698723 hasConceptScore W4315698723C42404028 @default.
• W4315698723 hasConceptScore W4315698723C44249647 @default.
• W4315698723 hasConceptScore W4315698723C71924100 @default.
• W4315698723 hasConceptScore W4315698723C76318530 @default.
• W4315698723 hasConceptScore W4315698723C90924648 @default.
• W4315698723 hasConceptScore W4315698723C98274493 @default.
• W4315698723 hasIssue "3" @default.
• W4315698723 hasLocation W43156987231 @default.
• W4315698723 hasLocation W43156987232 @default.
• W4315698723 hasLocation W43156987233 @default.
• W4315698723 hasOpenAccess W4315698723 @default.
• W4315698723 hasPrimaryLocation W43156987231 @default.
• W4315698723 hasRelatedWork W1989480569 @default.
• W4315698723 hasRelatedWork W1997101420 @default.

• next